Revvity, Inc. (RVTY)
| Market Cap | 10.24B |
| Revenue (ttm) | 2.80B |
| Net Income (ttm) | 285.20M |
| Shares Out | 117.87M |
| EPS (ttm) | 2.37 |
| PE Ratio | 37.55 |
| Forward PE | 16.81 |
| Dividend | $0.28 (0.32%) |
| Ex-Dividend Date | Oct 17, 2025 |
| Volume | 763,351 |
| Open | 86.56 |
| Previous Close | 86.46 |
| Day's Range | 85.67 - 87.41 |
| 52-Week Range | 85.12 - 129.50 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 121.86 (+40.33%) |
| Earnings Date | Jul 28, 2025 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company’s Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for tes... [Read more]
Financial Performance
In 2024, Revvity's revenue was $2.76 billion, an increase of 0.16% compared to the previous year's $2.75 billion. Earnings were $270.39 million, a decrease of -60.99%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $121.86, which is an increase of 40.33% from the latest price.
News
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSen...
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines R...
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More
U.S. equities were mhigher at midday after President Donald Trump and European Commission President Ursula von der Leyen announced a new trade agreement between the U.S. and the European Union. The Do...
Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY) Q2 2025 Earnings Conference Call July 28, 2025 8:00 AM ET Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad R. Singh - CEO, President & Director Stephen Barr ...
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Revvity trims 2025 profit forecast on soft demand for diagnostics in China
Medical equipment maker Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for its diagnostics products in some international markets to remain soft, sending the com...
Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.
The health sciences company posts better-than-expected adjusted earnings and revenue but trims its guidance.
Revvity Announces Financial Results for the Second Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as comp...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7,...
Revvity to Hold Earnings Call on Monday, July 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company w...
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or ...
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminesce...
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2...
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chie...
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop
Revvity Inc. RVTY stock is trading higher on Monday after the company reported better-than-expected first-quarter 2025 earnings.
Revvity beats quarterly estimates on steady demand for medical equipment
Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, helped by steady demand from biotech clients for medical equipment used for d...
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as comp...
Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, a leader in high-performance genomics solutions, today announced an important milestone in providing comprehensive and robust automated sol...
Revvity Fuels the Future of Cancer Science with New Research Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., is set to unveil the VivoJect™ Image-Guided Injection System as part of its distinguished cancer research and discovery portfolio at the AACR Annual Mee...
Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w...
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved ...
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™....
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.